Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Retraction Note: MEK1/2 regulate normal BCR and ABL1 tumor-suppressor functions to dictate ATO response in TKI-resistant Ph+ leukemia.

Leukemia·2026
Same author

Association Between Socioeconomic Inequalities and Health-Related Quality of Life in Patients With Relapsed/Refractory Multiple Myeloma.

JCO oncology practice·2026
Same author

Early Ibrutinib Dose Modifications in CLL: A Post Hoc Analysis of the Real-World EVIdeNCE Study.

Cancers·2026
Same author

Clinical Outcomes of Ruxolitinib Treatment in Patients With IPSS Intermediate-1-Risk Myelofibrosis: Interim Analysis From an Italian, Prospective Study (ROMEI).

Hematological oncology·2026
Same author

Incidence of severe COVID-19 in patients with chronic lymphocytic leukaemia or indolent B-cell non-Hodgkin lymphoma who received vaccination and pre-exposure prophylaxis with tixagevimab and cilgavimab in Italy: An observational study by the GIMEMA working party on chronic lymphoproliferative disorders and by the Fondazione Italiana Linfomi.

British journal of haematology·2026
Same author

A novel complex mutation affecting two codons in the exon 10 hotspot region of the MPL gene.

Current research in translational medicine·2025

Related Experiment Video

Updated: Jun 16, 2026

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
09:29

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Published on: September 30, 2016

Emerging MEK inhibitors.

James A McCubrey1, Linda S Steelman, Steven L Abrams

  • 1Brody School of Medicine at East Carolina University, Department of Microbiology & Immunology, 600 Moye Boulevard, Greenville, NC 27858, USA. mccubreyj@ecu.edu

Expert Opinion on Emerging Drugs
|February 16, 2010
PubMed
Summary
This summary is machine-generated.

Targeting MEK (mitogen-activated protein kinase kinase) effectively suppresses cell growth and apoptosis. MEK inhibitors show therapeutic potential for cancer, proliferative diseases, and aging.

More Related Videos

An Efficient Protocol to Assess ERK Activity Modulation in Early Zebrafish Noonan Syndrome Models via Live FRET Microscopy and Immunofluorescence
09:58

An Efficient Protocol to Assess ERK Activity Modulation in Early Zebrafish Noonan Syndrome Models via Live FRET Microscopy and Immunofluorescence

Published on: May 2, 2025

Related Experiment Videos

Last Updated: Jun 16, 2026

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
09:29

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Published on: September 30, 2016

An Efficient Protocol to Assess ERK Activity Modulation in Early Zebrafish Noonan Syndrome Models via Live FRET Microscopy and Immunofluorescence
09:58

An Efficient Protocol to Assess ERK Activity Modulation in Early Zebrafish Noonan Syndrome Models via Live FRET Microscopy and Immunofluorescence

Published on: May 2, 2025

Area of Science:

  • Molecular Biology
  • Oncology
  • Cellular Biology

Background:

  • The Ras/Raf/MEK/ERK pathway is frequently activated by genetic mutations in signaling molecules like Ras and B-Raf.
  • This pathway significantly influences cell proliferation, apoptosis, and differentiation.
  • MEK inhibitors offer a strategy to control this pathway's aberrant activity.

Purpose of the Study:

  • To review the scientific literature on targeting MEK for controlling abnormal proliferation.
  • To explore novel therapeutic strategies for cancer and other proliferative diseases.
  • To build upon previous reviews focusing on Raf inhibitors.

Main Methods:

  • Comprehensive literature review from 1980 to the present.
  • Analysis of studies investigating MEK inhibitors.
  • Synthesis of findings related to pathway modulation.

Main Results:

  • Understanding the genetic basis of patient response to MEK inhibitors.
  • Exploring combination therapies involving MEK inhibitors.
  • Investigating roles in preventing cellular aging and cancer stem cell development.

Conclusions:

  • Targeting MEK effectively inhibits key pathways in cell growth and apoptosis.
  • MEK inhibitors demonstrate significant therapeutic potential for cancer treatment.
  • Applications extend to managing proliferative diseases and age-related conditions.